395 related articles for article (PubMed ID: 16380591)
1. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.
Alexander KP; Chen AY; Roe MT; Newby LK; Gibson CM; Allen-LaPointe NM; Pollack C; Gibler WB; Ohman EM; Peterson ED;
JAMA; 2005 Dec; 294(24):3108-16. PubMed ID: 16380591
[TBL] [Abstract][Full Text] [Related]
2. Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative.
Singh KP; Roe MT; Peterson ED; Chen AY; Mahaffey KW; Goodman SG; Harrington RA; Smith SC; Gibler WB; Ohman EM; Pollack CV;
J Thromb Thrombolysis; 2006 Jun; 21(3):211-20. PubMed ID: 16683212
[TBL] [Abstract][Full Text] [Related]
3. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
Alexander KP; Chen AY; Newby LK; Schwartz JB; Redberg RF; Hochman JS; Roe MT; Gibler WB; Ohman EM; Peterson ED;
Circulation; 2006 Sep; 114(13):1380-7. PubMed ID: 16982940
[TBL] [Abstract][Full Text] [Related]
4. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
[TBL] [Abstract][Full Text] [Related]
5. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
[TBL] [Abstract][Full Text] [Related]
6. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
Silva MA; Donovan JL; Gandhi PJ; Volturo GA
Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet intervention in acute coronary syndrome.
Arora RR; Rai F
Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
[TBL] [Abstract][Full Text] [Related]
8. Doing the right things and doing them the right way: association between hospital guideline adherence, dosing safety, and outcomes among patients with acute coronary syndrome.
Mehta RH; Chen AY; Alexander KP; Ohman EM; Roe MT; Peterson ED
Circulation; 2015 Mar; 131(11):980-7. PubMed ID: 25688146
[TBL] [Abstract][Full Text] [Related]
9. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative.
Mehta RH; Roe MT; Chen AY; Lytle BL; Pollack CV; Brindis RG; Smith SC; Harrington RA; Fintel D; Fraulo ES; Califf RM; Gibler WB; Ohman EM; Peterson ED
Arch Intern Med; 2006 Oct; 166(18):2027-34. PubMed ID: 17030838
[TBL] [Abstract][Full Text] [Related]
10. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative.
Blomkalns AL; Chen AY; Hochman JS; Peterson ED; Trynosky K; Diercks DB; Brogan GX; Boden WE; Roe MT; Ohman EM; Gibler WB; Newby LK;
J Am Coll Cardiol; 2005 Mar; 45(6):832-7. PubMed ID: 15766815
[TBL] [Abstract][Full Text] [Related]
11. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
Almeda FQ; Hendel RC; Nathan S; Meyer PM; Calvin JE; Klein LW
J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Harrington RA; Becker RC; Cannon CP; Gutterman D; Lincoff AM; Popma JJ; Steg G; Guyatt GH; Goodman SG
Chest; 2008 Jun; 133(6 Suppl):670S-707S. PubMed ID: 18574276
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM;
JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591
[TBL] [Abstract][Full Text] [Related]
14. Managing acute coronary syndrome: evidence-based approaches.
Spinler SA
Am J Health Syst Pharm; 2007 Jun; 64(11 Suppl 7):S14-24. PubMed ID: 17519441
[TBL] [Abstract][Full Text] [Related]
15. Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes.
Melloni C; Alexander KP; Chen AY; Newby LK; Roe MT; Allen LaPointe NM; Pollack CV; Gibler WB; Ohman EM; Peterson ED;
Am Heart J; 2008 Aug; 156(2):209-15. PubMed ID: 18657648
[TBL] [Abstract][Full Text] [Related]
16. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
[TBL] [Abstract][Full Text] [Related]
17. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
Fitchett DH; Langer A; Armstrong PW; Tan M; Mendelsohn A; Goodman SG;
Am Heart J; 2006 Feb; 151(2):373-9. PubMed ID: 16442903
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of combined low molecular weight heparin and glycoprotein IIb/IIIa inhibitors.
Kovar D; Canto JG; Rogers WJ
Am J Cardiol; 2002 Nov; 90(9):911-5. PubMed ID: 12398953
[TBL] [Abstract][Full Text] [Related]
19. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
Stone GW; Bertrand ME; Moses JW; Ohman EM; Lincoff AM; Ware JH; Pocock SJ; McLaurin BT; Cox DA; Jafar MZ; Chandna H; Hartmann F; Leisch F; Strasser RH; Desaga M; Stuckey TD; Zelman RB; Lieber IH; Cohen DJ; Mehran R; White HD;
JAMA; 2007 Feb; 297(6):591-602. PubMed ID: 17299194
[TBL] [Abstract][Full Text] [Related]
20. Excess dosing of antithrombotic therapy in non-ST-segment elevation acute coronary syndromes.
Yan AT; Yan RT; Goodman SG
JAMA; 2006 Apr; 295(16):1896; author reply 1897. PubMed ID: 16639044
[No Abstract] [Full Text] [Related]
[Next] [New Search]
